Allogene Therapeutics (ALLO) Earnings Date, Estimates & Call Transcripts $1.94 +0.05 (+2.65%) Closing price 04:00 PM EasternExtended Trading$1.94 +0.01 (+0.26%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Allogene Therapeutics Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 12After Market ClosesEstimatedActual EPS (Mar. 13) -$0.28 Beat By $0.06 Consensus EPS (Mar. 13) -$0.34 Allogene Therapeutics announced Q4 2024 earnings on March 13, 2025, reporting an EPS of -$0.28, which topped analysts' consensus estimates of -$0.34 by $0.06. With a trailing EPS of -$1.56, Allogene Therapeutics' earnings are expected to decrease next year, from ($1.28) to ($1.35) per share. Conference CallConference Call TranscriptALLO Upcoming EarningsAllogene Therapeutics' next earnings date is estimated for Monday, May 12, 2025, based off prior year's reporting schedules. Get Allogene Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allogene Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataALLO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALLO Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Allogene Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.38-$0.33-$0.35Q2 20253-$0.38-$0.34-$0.36Q3 20253-$0.40-$0.35-$0.37Q4 20253-$0.43-$0.36-$0.38FY 202512-$1.59-$1.38-$1.46Q1 20261-$0.40-$0.40-$0.40Q2 20261-$0.43-$0.43-$0.43Q3 20261-$0.45-$0.45-$0.45Q4 20261-$0.47-$0.47-$0.47FY 20264($1.75)($1.75)($1.75) Remove Ads Allogene Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/12/2025(Estimated)-------3/13/2025Q4 2024-$0.34-$0.28+$0.06-$0.28$0.01M-8/7/2024Q2 2024-$0.35-$0.32+$0.03-$0.29--5/13/2024Q1 2024-$0.41-$0.38+$0.03-$0.38$0.01M$0.02M3/14/2024Q4 2023-$0.47-$0.43+$0.04-$0.35$0.05M$0.02M11/2/2023Q3 2023-$0.53-$0.37+$0.16-$0.37$0.05M$0.04M8/2/2023Q2 2023-$0.59-$0.53+$0.06-$0.53$0.01M$0.04M5/3/2023Q1 2023-$0.63-$0.68 -$0.05-$0.68$0.08M$0.05M Allogene Therapeutics Earnings - Frequently Asked Questions When is Allogene Therapeutics's earnings date? Allogene Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based off last year's report dates. Learn more on ALLO's earnings history. Did Allogene Therapeutics beat their earnings estimates last quarter? In the previous quarter, Allogene Therapeutics (NASDAQ:ALLO) reported ($0.28) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.34) by $0.06. Learn more on analysts' earnings estimate vs. ALLO's actual earnings. How can I listen to Allogene Therapeutics's earnings conference call? The conference call for Allogene Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Allogene Therapeutics's conference call transcript? The conference call transcript for Allogene Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded annual revenue of $43,000.00. How much profit does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded net income of -$327.27 million. ALLO has generated -$1.56 earnings per share over the last four quarters. What is Allogene Therapeutics's EPS forecast for next year? Allogene Therapeutics's earnings are expected to decrease from ($1.28) per share to ($1.35) per share in the next year. More Earnings Resources from MarketBeat Related Companies Tarsus Pharmaceuticals Earnings Results Arcutis Biotherapeutics Earnings Results Galapagos Earnings Results Apogee Therapeutics Earnings Results Disc Medicine Earnings Results Travere Therapeutics Earnings Results IDEAYA Biosciences Earnings Results Kiniksa Pharmaceuticals Earnings Results Schrödinger Earnings Results Immunocore Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Remove Ads This page (NASDAQ:ALLO) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
